Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
P/S ratio for Kiniksa Pharmaceuticals, Ltd. (KNSA)
P/S ratio as of 2023: 4.55
According to Kiniksa Pharmaceuticals, Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.55. At the end of 2022 the company had a P/S ratio of 4.72.
P/S ratio history for Kiniksa Pharmaceuticals, Ltd. from 2016 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 4.55 |
| 2022 | 4.72 |
| 2021 | 20.94 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |